US2004053998A1PendingUtilityA1

Lipoxin analogs as novel inhibitors of angiogenesis

51
Priority: Mar 2, 2001Filed: Jul 8, 2003Published: Mar 18, 2004
Est. expiryMar 2, 2021(expired)· nominal 20-yr term from priority
Inventors:Charles N. SerhanIolanda Fierro
A61P 9/00A61P 9/10A61P 35/00A61P 43/00A61P 9/08A61P 27/02A61P 17/02A61K 31/203A61K 31/20A61K 31/202
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A 4 , LXA 4 , 15-epi-LXA 4 or 15-R/S-methyl, LXA 4 and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof. As a consequence of the action of the therapeutic agent, angiogenesis is prevented or inhibited in the subject.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method to prevent, reduce or inhibit angiogenesis comprising the step of administering to a subject an effective amount of a lipoxin A 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that angiogenesis is prevented, reduced or inhibited in the subject.  
     
     
         2 . The method of  claim 1 , wherein the lipoxin A 4  compound is LXA 4  or 15-R/S-methyl, LXA 4 .  
     
     
         3 . A method to prevent, reduce or inhibit angiogenesis comprising the step of administering to a subject an effective amount of a 15-epi-lipoxin A 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that angiogenesis is prevented, reduced or inhibited in the subject.  
     
     
         4 . The method of  claim 3 , wherein the 15-epi-lipoxin A 4  compound is 15-epi-16-(para-fluoro)-phenoxy-lipoxin A 4 .  
     
     
         5 . A method for treating a subject for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty, comprising administering to said subject a composition comprising an effective amount of a lipoxin A 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty is prevented, reduced, or inhibited.  
     
     
         6 . The method of  claim 5 , wherein the lipoxin A 4  compound is LXA 4  or 15-R/S-methyl, LXA 4 .  
     
     
         7 . A method for treating a subject for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty, comprising administering to said subject a composition comprising an effective amount of a 15-epi-lipoxin A 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty is prevented, reduced, or inhibited.  
     
     
         8 . The method of  claim 7 , wherein the 15-epi-lipoxin A 4  compound is 15-epi-16-(para-fluoro)-phenoxy-lipoxin A 4 .  
     
     
         9 . A method to facilitate wound healing in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that wound healing in the subject is facilitated.  
     
     
         10 . The method of  claim 9 , wherein the LXB 4  compound is selected from the group consisting of 14-epi-LXB 4 , 15-epi-LXB 4  and 15-epi-LXB 4 -acetylenic.  
     
     
         11 . A method to facilitate angiogenesis in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that angiogenesis in the subject is facilitated.  
     
     
         12 . The method of  claim 11 , wherein LXB 4  is excluded.  
     
     
         13 . The method of  claim 11 , wherein the LXB 4  compound is selected from the group consisting of 14-epi-LXB 4 , 15-epi-LXB 4  and 15-epi-LXB 4 -acetylenic.  
     
     
         14 . A method to facilitate neovascularization in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that neovascularization in the subject is facilitated.  
     
     
         15 . The method of  claim 14 , wherein LXB 4  is excluded.  
     
     
         16 . The method of  claim 14 , wherein the LXB 4  compound is selected from the group consisting of 14-epi-LXB 4 , 15-epi-LXB 4  and 15-epi-LXB 4 -acetylenic.  
     
     
         17 . A method to facilitate cardiac revascularization in a subject comprising the step of administering to the subject in need thereof, an effective amount of an LXB 4  compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that cardiac revascularization in the subject is facilitated.  
     
     
         18 . The method of  claim 17 , wherein the LXB 4  compound is selected from the group consisting of 14-epi-LXB 4 , 15-epi-LXB 4  and 15-epi-LXB 4 -acetylenic

Join the waitlist — get patent alerts

Track US2004053998A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.